Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
PRGO 
Perrigo Company PLC (PRGO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: PRGO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -48.4% | Avg. Invested days 27 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.78B USD | Price to earnings Ratio - | 1Y Target Price 34.6 |
Price to earnings Ratio - | 1Y Target Price 34.6 | ||
Volume (30-day avg) 2029839 | Beta 0.47 | 52 Weeks Range 22.91 - 32.16 | Updated Date 04/1/2025 |
52 Weeks Range 22.91 - 32.16 | Updated Date 04/1/2025 | ||
Dividends yield (FY) 4.14% | Basic EPS (TTM) -1.17 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -3.93% | Operating Margin (TTM) 23.61% |
Management Effectiveness
Return on Assets (TTM) 2.55% | Return on Equity (TTM) -3.54% |
Valuation
Trailing PE - | Forward PE 9.43 | Enterprise Value 6839203774 | Price to Sales(TTM) 0.86 |
Enterprise Value 6839203774 | Price to Sales(TTM) 0.86 | ||
Enterprise Value to Revenue 1.56 | Enterprise Value to EBITDA 15.79 | Shares Outstanding 136459008 | Shares Floating 135743577 |
Shares Outstanding 136459008 | Shares Floating 135743577 | ||
Percent Insiders 0.34 | Percent Institutions 101.19 |
Analyst Ratings
Rating 4 | Target Price 34.2 | Buy 2 | Strong Buy 2 |
Buy 2 | Strong Buy 2 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Perrigo Company PLC
Company Overview
History and Background
Perrigo Company PLC was founded in 1887 as a packaging company in Allegan, Michigan. Over time, it evolved into a leading manufacturer of over-the-counter (OTC) pharmaceuticals and consumer healthcare products.
Core Business Areas
- Consumer Self-Care Americas (CSCA): Focuses on manufacturing and marketing store brand, self-care products including cough, cold, allergy, pain relief, gastrointestinal, and vitamins, minerals, and supplements (VMS).
- Consumer Self-Care International (CSCI): Focuses on manufacturing and marketing store brand self-care products internationally.
Leadership and Structure
Perrigo is led by a CEO and supported by a management team overseeing various functional areas. The organizational structure includes business unit leaders for CSCA and CSCI, as well as functional heads for finance, operations, and research and development.
Top Products and Market Share
Key Offerings
- Cough, Cold, and Allergy: Includes store-brand equivalents of popular OTC medications. Competitors include Johnson & Johnson, Procter & Gamble, and GSK. Market share varies widely by specific product but Perrigo holds a significant share of store brand equivalents.
- Pain Relief: Includes store-brand equivalents of pain relievers such as ibuprofen, acetaminophen, and naproxen. Competitors include Johnson & Johnson, Bayer, and GSK. Similar to cough/cold, Perrigo holds a significant share of store brand equivalents in pain relief.
- Infant Formula: Perrigo also manufactures Infant Formula. Mead Johnson and Abbot are competitors.
Market Dynamics
Industry Overview
The OTC pharmaceutical and consumer healthcare industry is characterized by steady growth, driven by aging populations, increasing healthcare costs, and a growing preference for self-medication.
Positioning
Perrigo is positioned as a leading manufacturer of store-brand OTC products, offering cost-effective alternatives to branded medications. Its competitive advantage lies in its efficient manufacturing capabilities and strong relationships with retailers.
Total Addressable Market (TAM)
The global OTC market is estimated to be over $150 billion. Perrigo is positioned to capture a portion of this TAM through its broad product portfolio and focus on store brands.
Upturn SWOT Analysis
Strengths
- Strong manufacturing capabilities
- Extensive distribution network
- Cost-effective product portfolio
- Strong relationships with retailers
Weaknesses
- Dependence on store-brand products
- Vulnerability to pricing pressure
- Potential for product liability issues
- Debt load from acquisitions
Opportunities
- Expanding into new geographic markets
- Developing innovative OTC products
- Acquiring complementary businesses
- Benefiting from increasing demand for self-care solutions
Threats
- Increased competition from branded and generic manufacturers
- Regulatory changes affecting OTC products
- Economic downturns impacting consumer spending
- Supply chain disruptions
Competitors and Market Share
Key Competitors
- JNJ
- BAYRY
- GSK
Competitive Landscape
Perrigo's advantage lies in its cost-effective store-brand offerings. Disadvantages include a lower brand recognition compared to branded competitors.
Major Acquisitions
HRA Pharma
- Year: 2022
- Acquisition Price (USD millions): 2100
- Strategic Rationale: Expanded Perrigo's portfolio of self-care brands and strengthened its presence in Europe.
Growth Trajectory and Initiatives
Historical Growth: Perrigo's historical growth has been driven by acquisitions and organic growth in its core OTC business.
Future Projections: Future growth projections depend on factors such as market trends, competitive dynamics, and Perrigo's strategic initiatives. Analyst estimates provide a range of potential growth rates.
Recent Initiatives: Recent strategic initiatives may include product launches, acquisitions, and cost-saving measures.
Summary
Perrigo is a major player in the OTC market with strong manufacturing capabilities, but its dependence on store brands makes it vulnerable to pricing pressures. Its strategic acquisitions have expanded its product portfolio and geographic reach. Maintaining operational efficiency and investing in innovation are critical for continued growth, along with navigating intense competition and regulatory changes.
Similar Companies
GSK
GlaxoSmithKline PLC ADR
GSK
GlaxoSmithKline PLC ADR
JNJ
Johnson & Johnson
JNJ
Johnson & Johnson
PFE
Pfizer Inc
PFE
Pfizer Inc
Sources and Disclaimers
Data Sources:
- Company filings
- Industry reports
- Analyst estimates
- Perrigo Website
- SEC Filings
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Perrigo Company PLC
Exchange NYSE | Headquaters - | ||
IPO Launch date 1991-12-16 | President, CEO & Director Mr. Patrick Lockwood-Taylor | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 8379 | Website https://www.perrigo.com |
Full time employees 8379 | Website https://www.perrigo.com | ||
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.